Iakovos Toumazis, Ph.D.
Department of Health Services Research, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Adjunct Assistant Professor, Department of Computational Applied Mathematics & Operations Research, Division of Cancer Prevention and Population Sciences, Rice University, TX
Assistant Professor, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | University of Buffalo, SUNY, Buffalo, New York, US, Ph.D. in Industrial Engineering |
| 2012 | University of Buffalo, SUNY, Buffalo, New York, US, M.S. in Industrial Engineering |
| 2009 | University of Patras, Patras, GR, BS in Mathematics |
Postgraduate Training
| 2015-2020 | Postdoctoral Research Fellow, Stanford University, Stanford, California |
Experience & Service
Other Appointments/Responsibilities
Institute for Data Science in Oncology (IDSO) Affiliate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Graduate Assistant, Industrial Engineering, Goodwill Industries of Western New York, Buffalo, NY, 2011 - 2012
Institutional Committee Activities
Member, MedTech Innovation Council, 2024 - Present
Member, Forecasting and Decision Sciences for the Health of Individuals and Societies, 2024 - 2024
Member, CCSG Gyn Cancers Program Retreat, 2023 - 2024
Member, Department of Health Services Research, 2023 - Present
Member, Department of Epidemiology, 2022 - Present
Member, DCPPS Employee Recognition Awards Review Board, 2022 - 2022
Member, Lung Cancer Screening Task Force, 2021 - Present
Member, Internal Advisory Board for the Shared Decision Making Core, MDACC Cancer Center Support Grant (CCSG), 2021 - Present
Member, Lung Cancer Early Detection Working Group, 2021 - Present
Member, Integrative Biomedical Imagine Informatics at Stanford (IBIIS) Annual Retreat Organizing Committee, 2018 - 2018
Honors & Awards
| 2018 | Best Poster Award, Integrative Biomedical Imagine Informatics at Stanford (IBIIS) Annual Retreat, Stanford University |
| 2015 | Institute of industrial Engineers Doctor Colloquium |
| 2015 | Winner of the Society for Health Systems Best Graduate Student Paper Competition |
| 2012 | University Transportation Research Center (UTRC) Travel Award |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Tan NQP, Nargund RS, Douglas EE, Lopez-Olivo MA, Resong PJ, Ishizawa S, Nofal S, Krause K, Volk RJ, Toumazis I. Acceptability and perceptions of personalised risk-based cancer screening among health-care professionals and the general public: a systematic review and meta-analysis. Lancet Public Health 10(2):e85-e96, 2025. e-Pub 2025. PMID: 39909697.
- Gendarme S, Irajizad E, Long JP, Fahrmann JF, Dennison JB, Ghasemi SM, Dou R, Volk RJ, Meza R, Toumazis I, Canoui-Poitrine F, Hanash SM, Ostrin EJ. Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials. J Thorac Oncol 1556-0864(25):00004-8, 2025. PMID: 39798695.
- Adjei NN, Haas A, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Health care costs in the United States by demographic characteristics and comorbidity status. Value in Health 28(2):206-214, 2024. e-Pub 2024. PMID: 39532216.
- Irajizad, E, Fahrmann, JF, Toumazis, I, Vykoukal, JV, Dennison, JB, Shen, Y, Do, K, Ostrin, EJ, Feng, Z, Hanash, SM. Biomarker trajectory for earlier detection of lung cancer. EBioMedicine 108, 2024. e-Pub 2024. PMID: 39353277.
- Adjei, Haas, Sun, Zhao, Yeh, Giordano, Toumazis, Meyer. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol S0002-9378(24):00846-9, 2024. e-Pub 2024. PMID: 39159781.
- Hemmati, M, Ishizawa, S, Meza, R, Ostrin, EJ, Hanash, S, Antonoff, MB, Schaefer, AJ, Tammemagi, M, Toumazis, I. Benchmarking lung cancer screening programmes with adaptive screening frequency against the optimal screening schedules derived from the ENGAGE framework. EClinicalMedicine 74, 2024. e-Pub 2024. PMID: 39764179.
- Ishizawa S, Niu J, Tammemagi, Irajizad E, Shen Y, Lu KH, Meyer, Toumazis. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. JNCI 00(0):1-9, 2024. e-Pub 2024. PMID: 39038822.
- Ten Haaf K, de Nijs K, Simoni G, Alban A, Cao P, Sun Z, Yong J, Jeon J, Toumazis I, Han SS, Gazelle GS, Kong CY, Plevritis SK, Meza R, de Koning HJ. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations. Medical Decision Making 44(5):497-511, 2024. e-Pub 2024. PMID: 38738534.
- Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Research Square, 2024. e-Pub 2024. PMID: 38798564.
- Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer : Proof of concept. Cell Reports Medicine 5(3):101463, 2024. e-Pub 2024. PMID: 38471502.
- Nofal, S, Niu, J, Resong, PJ, Jin, J, Merriman, K, Le, X, Katki, HA, Heymach, JV, Antonoff, MB, Ostrin, EJ, Wu, J, Zhang, J, Toumazis, I. Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening. Cancer Med 13(5):E7069, 2024. e-Pub 2024. PMID: 38466021.
- Resong, PJ, Niu, J, Duhon, GF, Foxhall, LE, Shete, S, Volk, R, Toumazis, I. Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers. Cancer Prevention Research 17(2):51-57, 2024. e-Pub 2024. PMID: 38212272.
- Maki KG, Tan NQP, Toumazis I, Volk RJ. Prevalence of lung cancer screening in 4 states in the U.S.: A Cross-sectional analysis from the 2021 Behavioral Risk Factor Surveillance System. JAMA Netw Open 6(6):e2319172, 2023. e-Pub 2023. PMID: 37342043.
- Toumazis I, Cao P, de Nijs K, Bastani M, Munshi V, Hemmati M, Ten Haaf K, Jeon J, Tammemägi M, Gazelle GS, Feuer EJ, Kong CY, Meza R, de Koning HJ, Plevritis SK, Han SS. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Ann Intern Med 176(3):320-332, 2023. e-Pub 2023. PMID: 36745885.
- Maki KG, Talluri R, Toumazis I, Shete S, Volk RJ. Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility. Cancer Med 12(4):4647-4654, 2023. e-Pub 2023. PMID: 35871312.
- Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol 7(12):1833-1842, 2021. e-Pub 2021. PMID: 34673885.
- Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer 127(23):4432-4446, 2021. e-Pub 2021. PMID: 34383299.
- Bastani M, Toumazis I, Hedou' J, Leung A, Plevritis SK. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. J Am Coll Radiol 18(12):1614-1623, 2021. e-Pub 2021. PMID: 34419477.
- Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SK. A Cost-Effectiveness Analysis of Lung Cancer Screening with Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectr 5(6), 2021. e-Pub 2021. PMID: 34738073.
- Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
- Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA 325(10):988-997, 2021. e-Pub 2021. PMID: 33687469.
- Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. J Natl Cancer Inst 112(11):1136-1142, 2020. e-Pub 2020. PMID: 32040195.
- Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. J Natl Cancer Inst 112(5):466-479, 2020. e-Pub 2020. PMID: 31566216.
- Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med 171(11):796-804, 2019. e-Pub 2019. PMID: 31683314.
- Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectrum 3(3):pkz035, 2019. e-Pub 2019. PMID: 31942534.
- Tammemägi MC, Ten Haaf K, Toumazis I, Kong CY, Han SS, Jeon J, Commins J, Riley T, Meza R. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. JAMA Network Open 2(3):e190204, 2019. e-Pub 2019. PMID: 30821827.
- Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy & Practice 2(2):2381468317729650, 2017. e-Pub 2017. PMID: 30288431.
- Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes & Control 28(9):947-958, 2017. e-Pub 2017. PMID: 28702814.
- Toumazis, I, Kwon, C. Worst-case conditional value-At-risk minimization for hazardous materials transportation. Transportation Science 50(4):1174-1187, 2016. e-Pub 2016.
- Toumazis, I, Kwon, C. Routing hazardous materials on time-dependent networks using conditional value-at-risk. Transportation Research Part C: Emerging Technologies 37:73-92, 2013. e-Pub 2013.
- Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res. PMID: 39930864.
Other Articles
- Toumazis I, Bastani M, Han SS, Plevritis SK Risk-Based lung cancer screening: A systematic review. Lung Cancer 147:154-186, 2020. PMID: 32721652.
Editorials
- Maki KG, Tan NQP, Volk RJ, Toumazis I. Examining Lung Cancer Screening Uptake in the United States: Recent Research and Limitations of Public-Use Data. Cancer Epidemiol Biomarkers Prev. Cancer Epidemiol Biomarkers Prev 34(1):9-11, 2025. PMID: 39780617.
Book Chapters
- Toumazis I, Kwon C, Batta R. Value-at-risk and Conditional Value-at-Risk Minimization for Hazardous Materials Routing. In: Handbook of OR/MS Models in Hazardous Materials Transportation (Eds.: R. Batta and C. Kwon. Springer, 2013.
Selected Presentations & Talks
Local Presentations
- 2025. Decision Analytic model for indeterminate findings. Conference. Personalized Lung Cancer Screening: Project Annual ENGAGE. Houston, Texas, US.
- 2025. Integrating non-smoking related risk factors into ENGAGE. Conference. Personalized Lung Cancer Screening: Project Annual ENGAGE. Houston, Texas, US.
- 2024. Trends in Family History of Lung Cancer & Competing Comorbidities. Conference. Houston, Texas, US.
- 2024. Calibration of Histology-Specific Natural History Models for Ovarian Cancer Using Simulated Annealing Algorithm. Poster. CCSG GI Cancer Retreat. Houston, TX, US.
- 2024. Evaluation of Refined PLCOm2012 Models for ENGAGE in Mexican American Smokers using Mano-a-Mano Cohort. Conference. ENGAGE Annual Meeting. Houston, Texas, US.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Invited. EDRN Site Meeting. Houston, Texas, US.
- 2023. Personalized Lung Cancer Screening: Project Engage. Invited. Health Services Research Seminar Series. Houston, TX, US.
- 2023. Personalized Lung Cancer Screening: The ENGAGE Framework. Invited. 2023 EDRN Lung CVC Meeting. Houston, TX, US.
- 2023. Development of an Ovarian Cancer Risk Prediction Model. Conference. Cancer Center Support Grant (CCSG). Houston, Texas, US.
- 2022. Informing Lung Cancer Screening Policy Using Decision-Analytic Models. Invited. Cancer Prevention and Control Grand Rounds. Houston, TX, US.
- 2022. Personalized Lung Cancer Screening Acceptability among Primary Care Providers. Poster. MD Anderson Summer Experience Final Exposition. Houston, Texas, US.
- 2022. Personalized Lung Cancer Screening Acceptability among Primary Care Providers. Poster. Cancer Prevention Research Training Program Summer Trainee Exposition. Houston, Texas, US.
National Presentations
- 2024. Predicting lung cancer risk with CT radiomics: implications for immunoprevention. Poster. Society for Immunotherapy of Cancer's 39th Annual Meeting 2024. Houston, TX, US.
- 2024. The ENGAGE Framework: Personalizing Lung Cancer Screening. Invited. 2024 CISNET Mid-Year Meeting. Rockville, Maryland, US.
- 2023. The ENGAGE Framework (Revisited). Conference. 2023 CISNET Annual Meeting. Rockville, Maryland, US.
- 2023. A four-protein blood biomarker panel refines a clinical risk score for indeterminate pulmonary nodules. Poster. Gaithersburg, MD, US.
- 2023. The ENGAGE Framework; The impact of screening structure on the performance of lung cancer screening. Conference. 2023 CISNET Mid-Year Meeting. Seattle, WA, US.
- 2023. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. Poster. 2023 ASCO Annual Meeting. Chicago, IL, US.
- 2023. Lung cancer screening status and acceptability of a personalized approach in Texas. Conference. 2023 ASCO Annual Meeting. Chicago, IL, US.
- 2023. Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention. Conference. 2023 AACR Annual Meeting. Orlando, FL, US.
- 2022. Impact of Adherence on the Cost-Effectiveness of the Lung Cancer Screening Program: An exploratory analysis,. Conference. 2022 CISNET Annual Meeting, Virtual Meeting, NCI, US.
- 2021. Cost-Effectiveness Analysis of Risk-Based Lung Cancer Screening. Conference. 2021 CISNET Annual Meeting, NCI. Virtual, US.
- 2021. Personalizing Lung Cancer Screening Using a Decision-Analytic Model: Insights from the ENGAGE Framework,. Conference. 2021 CISNET Mid-Year Meeting, NCI. Virtual, US.
- 2021. Cost-Effectiveness of Risk-Based Lung Cancer Screening,. Conference. 2021 CISNET Annual Meeting , NCI, US.
- 2020. Personalized Adaptive Lung Cancer Screening: Insights from the ILungSS framework. Conference. 2020 CISNET Annual Meeting. Rockville, MD, US.
- 2020. Cost-Effectiveness of Risk-Based Lung Cancer Screening. Conference. 2020 CISNET Mid-Year Meeting. Virtual, US.
- 2019. Insights from a fully dynamic screening framework. Conference. 2019 CISNET Annual Meeting. Rockville, MD, US.
- 2019. Model Accessibility. Conference. 2019 CISNET Mid-Year Meeting. Seattle, WA, US.
- 2018. Personalizing Lung Cancer Screening Using a Partially Observable Markov Decision Process (POMDP). Conference. 2018 CISNET Annual Meeting. Rockville, MD, US.
- 2018. Cost-Effectiveness of Lung Cancer Screening Supplemented by a Hypothetical Diagnostic Biomarker. Conference. 2018 CISNET Annual Meeting. Rockville, MD, US.
- 2015. Assessing the role of sequencing up to three lines of chemotherapy in metastatic colorectal cancer treatment: A cost-effectiveness analysis. Conference. The 37th Annual Meeting of the Society of Medical Decision Making. St.Louis, Missouri, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 IIE Annual Conference. Nashville, TN, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 Healthcare Systems Process Improvement Conference. Orlando, FL, US.
- 2014. Eliciting cholesterol management guidelines' valuation of future life. Conference. The 36th Annual Meeting of the Society for Medical Decision Making. Miami, FL, US.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. 2012 IIE Annual Conference. Orlando, FL, US.
International Presentations
- 2025. Cost-effectiveness analysis of the addition of metastasis directed therapy to intermittent hormone therapy for oligometastatic prostate cancer. Poster. 2025 American College of Radiation Oncology (ACRO) annual conference. Las Vegas, US.
- 2024. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. Invited. INFORMS Annual Meeting 2024. Seattle, US.
- 2024. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. Conference. Seattle, US.
- 2024. Calibration of Histology Specific Natural History Models for Ovarian Cancer Using Simulated Annealing. Conference. Phoenix, US.
- 2024. A four-protein blood biomarker panel refines a clinical risk score for indeterminate pulmonary nodules. Conference. San Diego, US.
- 2024. Lung Cancer Screening Eligibility and Use in the US: A Cross-Sectional Analysis of 2022 Behavioral Risk Factor Surveillance System Data. Poster. ISPOR 2024 international conference. Atlanta, US.
- 2024. Opportunistic Salpingectomy During Gynecologic and Non-Gynecologic Abdominopelvic Procedures for Ovarian Cancer Primary Prevention: A Cost-Effectiveness Analysis. Conference. San Diego, US.
- 2023. Optimizing Lung Cancer Screening Schedules at the Individual-Level Using an Expanded Version of Engage, a Personalized Screening Decision Tool. Conference. Toronto, CA.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Conference. Toronto, CA.
- 2023. The Impact of Practicality on the Effectiveness and Efficiency of Lung Cancer Screening Programs. Conference. Turin, IT.
- 2023. Lung cancer screening among non-eligible Head and Neck cancer patients based on the 2021 US Preventive Services Task Force eligibility criteria. Conference. Turin, IT.
- 2023. Disparities in Levonorgestrel-Releasing Intrauterine System Use (LNG-IUS) among American Women: Implications for Endometrial Cancer Prevention. Conference. Orlando, US.
- 2023. Development of an Ovarian Cancer Risk Prediction Model. Conference. INFORMS Annual Meeting. Phoenix, US.
- 2023. Assessing the Loss in Effectiveness and Efficiency of Lung Cancer Screening by Enforcing a Structure on the Screening Policy. Conference. INFORMS Annual Meeting. Phoenix, US.
- 2023. The Engage Framework for Personalizing Lung Cancer Screening. Conference. INFORMS Annual Meeting. Phoenix, US.
- 2022. The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program. Conference. Vienna, AT.
- 2021. Evaluation of alternative diagnostic test intervals and thresholds for Lung-RADS criteria on the effectiveness of lung cancer screening. Conference. 2021 World Conference on Lung Cancer, Worldwide Virtual Event, US.
- 2021. Accounting for Racial Differences in Optimizing Lung Cancer Screening Schedules. Conference. INFORMS Healthcare Meeting, Virtual Meeting, US.
- 2021. Personalized optimal lung cancer screening schedules: Study of implementable strategies via enforcing policy structure. Conference. INFORMS. Anaheim, US.
- 2019. Disparities and National Lung Cancer Screening Guidelines in the U.S. Population. Conference. Barcelona, ES.
- 2019. Personalized lung cancer screening strategies using a partially observable Markov decision process. Conference. 2019 INFORMS Healthcare Meeting. Cambridge, US.
- 2019. Evaluation of Alternative Subsequent Screening for LungRADS Criteria on the Effectiveness of Lung Cancer Screening. Conference. 2019 INFORMS Healthcare Meeting. Cambridge, US.
- 2019. Individualized Risk-Based Lung Cancer Screening Incorporating Past Screening Findings and Changes in Smoking Behaviors. Conference. Barcelona, ES.
- 2018. Evaluation of alternative diagnostic test intervals and thresholds for Lung-RADS criteria on the effectiveness of lung cancer screening. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2018. Personalized lung cancer screening strategies using a partially observable Markov decision process. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2018. The effect of indeterminate findings on the cost-effectiveness of lung cancer screening. Conference. 2018 INFORMS Annual Meeting. Phoenix, US.
- 2017. Impact Of False-Positives On The Cost-effectiveness of Lung Cancer Screening. Conference. Rotterdam, NL.
- 2016. Impact Of False-Positives On The Cost-effectiveness of Lung Cancer Screening. Conference. 2016 INFORMS Annual Meeting. Houston, US.
- 2016. Evaluating the impact of diagnostic biomarkers on the cost-effectiveness efficiency frontier of alternative lung cancer screening strategies. Conference. Hawaii, US.
- 2016. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. Hawaii, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. 2015 INFORMS Annual Meeting. Philadelphia, US.
- 2015. A dynamic programming approach to palliative chemotherapy scheduling for metastatic colorectal cancer patients. Conference. Toronto, CA.
- 2014. Eliciting cholesterol management guidelines' valuation of future life. Conference. 2014 INFORMS Annual Meeting. San Francisco, US.
- 2013. Advanced risk measures applied in hazardous materials routing. Conference. 2013 INFORMS Annual Meeting. Minneaspolis, US.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. 2012 INFORMS Annual Meeting. Phoenix, US.
- 2012. Conditional value-at-risk for hazardous materials transportation on time-dependent networks. Conference. Niagara Falls, ON, CA.
- 2011. Worst case conditional value-at-risk minimization in hazardous materials transportation. Conference. 2011 INFORMS Annual Meeting. Charlotte, US.
Formal Peers
- 2023. Optimization of Lung Cancer Screening Using Principles from Operations Research. Dallas, Texas, US.
- 2023. Applications of mathematical models in the context of lung cancer screening. Invited. Applications of mathematical models in the context of lung cancer screening. Houston, TX, US.
- 2023. Changing the paradigm of lung cancer prevention using mathematical models, CyBioS Mini Symposium 2023 CancerNow: From Benchside to Clinical Applications. Invited. Changing the paradigm of lung cancer prevention using mathematical models, CyBioS Mini Symposium 2023 CancerNow: From Benchside to Clinical Applications, CY.
- 2021. Personalizing Lung Cancer Screening Using a Decision-Analytic Model: Insights from the ENGAGE Framework, ClubMeth Seminar Series. Invited. Personalizing Lung Cancer Screening Using a Decision-Analytic Model: Insights from the ENGAGE Framework, ClubMeth Seminar Series, US.
- 2019. The Future of Lung Cancer Screening: Is Personalized Screening Necessary and Feasible?. Invited. The Future of Lung Cancer Screening: Is Personalized Screening Necessary and Feasible?. Rockville, MD, US.
- 2019. Personalized Lung Cancer Screening: The Individualized Lung Screening Scheduler (ILungSS). Invited. Personalized Lung Cancer Screening: The Individualized Lung Screening Scheduler (ILungSS). Seattle, WA, US.
- 2019. Lung Cancer Screening: Is Individualized Screening a Feasible Solution to Existing Problems?. Invited. Lung Cancer Screening: Is Individualized Screening a Feasible Solution to Existing Problems?. Houston, TX, US.
- 2019. A New Paradigm in Lung Cancer Screening: Screening for Individuals not Populations. Invited. A New Paradigm in Lung Cancer Screening: Screening for Individuals not Populations. Buffalo, NY, US.
- 2018. Personalizing Lung Cancer Screening Using a Partially Observable Markov Decision Process. Invited. Personalizing Lung Cancer Screening Using a Partially Observable Markov Decision Process. Stanford, CA, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | Optimizing Population Selection for Primary (Helicobacter Pylori Screening) and Secondary (endoscopic Screening and Surveillance) Prevention of Gastric Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP220127 |
| Date: | 2023 - 2024 |
| Title: | Lung Moon Shot Expanding Reach |
| Funding Source: | Moon Shot Program |
| Role: | Co-Leader |
| Date: | 2023 - 2028 |
| Title: | Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Multi-Principal Investigator |
| ID: | RP230213 |
| Date: | 2022 - 2025 |
| Title: | Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions |
| Funding Source: | NIH/NCI |
| Role: | Subcontract Principal Investigator |
| ID: | U01CA253858 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Lung Cancer Early Detection |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01CA271888 |
| Date: | 2022 - 2027 |
| Title: | Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R37CA271187 |
| Date: | 2022 - 2024 |
| Title: | Development of a risk prediction and natural history models for ovarian cancer |
| Funding Source: | Duncan Family Institute for Cancer Prevention and Risk Assessment Seed-Funding Research Program |
| Role: | PI |
| Date: | 2022 - 2024 |
| Title: | Establishing the Value of Proton Therapy for Head and Neck Cancer: Assessing Cost-Effectiveness and Financial Toxicity of Therapy |
| Funding Source: | National Association for Proton Therapy (NAPT) |
| Role: | CO-I |
| Date: | 2022 - 2025 |
| Title: | Understanding and Intercepting Ovarian Carcinogenesis” The BTC Minimal Original Disease (MOD) Ovarian Cancer Team |
| Funding Source: | Break Through Cancer (BTC) |
| Role: | Collaborator |
| Date: | 2021 - 2022 |
| Title: | Acceptability Assessment and Delivery of Personalized Lung Cancer Screening |
| Funding Source: | Cancer Center Support Grant: Risk Detection and Outcomes (RDO) Program |
| Role: | Co-PI |
| ID: | P30CA016672 |
| Date: | 2021 - 2022 |
| Title: | Smoking Cessation and Lung Cancer Screening for Dental Patients |
| Funding Source: | The University of Texas Health Science Center (UTHealth)-MD Anderson Cancer Center (MDACC) Population Health Initiative |
| Role: | Investigator |
| ID: | UTH-MDA Population health Initiative Quick Start Award |
| Date: | 2021 - 2022 |
| Title: | Lung Moon Shot Expanding Reach |
| Funding Source: | MD Anderson Cancer Center Moonshot Program |
| Role: | CO-I |
| Date: | 2020 - 2023 |
| Title: | Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions |
| Funding Source: | Cancer Intervention and Surveillance Modeling Network (CISNET) |
| Role: | CO-I |
| ID: | 5U01 CA199284-05 |
| Date: | 2019 - 2020 |
| Title: | Comparative Modeling: Informing Breast Cancer Control Practice and Policy |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | U01 CA199218 |
| Date: | 2019 - 2020 |
| Title: | Administrative Supplement to Controlling Esophageal Cancer: A Collaborative Modeling Approach |
| Funding Source: | NIH/NCI |
| Role: | Consultant |
| ID: | U01 CA199336 |
| Date: | 2017 - 2019 |
| Title: | Personalized, Dynamic Risk-based Lung Cancer Screening |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | F32 CA220961 |
| Date: | 2015 - 2020 |
| Title: | Comparative Modeling of Lung Cancer Prevention and Control Policies |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
| ID: | U01CA199284 |
Patient Reviews
CV information above last modified March 20, 2025